Xenon Pharmaceuticals Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Xenon Pharmaceuticals Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2021 to Q3 2024.
  • Xenon Pharmaceuticals Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $10.6M, a 49.6% increase year-over-year.
  • Xenon Pharmaceuticals Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $41.7M, a 40.4% increase year-over-year.
  • Xenon Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2023 was $31.4M, a 707% increase from 2022.
  • Xenon Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2022 was $3.89M, a 3603% increase from 2021.
  • Xenon Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2021 was $105K, a 95.2% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $41.7M $10.6M +$3.5M +49.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $38.2M $10.8M +$2.9M +36.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $35.3M $11.5M +$3.91M +51.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $31.4M $8.75M +$1.67M +23.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $29.7M $7.07M +$6.67M +1707% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $23M $7.94M +$8.83M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $14.2M $7.61M +$10.3M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $3.89M $7.08M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $391K +$443K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$883K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$2.7M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 -$52K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.